You are here

  • Home
  • Archive
  • Volume 81, Issue Suppl 1
  • OP0019 BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY

Article metrics

Article menu

Download PDFPDF

Scientific Abstracts
Oral Presentations
AxSpA drug treatment: new and old drugs
OP0019 BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY
Free

 

Online download statistics by month:

Online download statistics by month: May 2022 to March 2024

AbstractFullPdf
May 20222800
Jun 2022205043
Jul 2022143033
Aug 2022106048
Sep 2022194031
Oct 2022185033
Nov 2022119025
Dec 2022119017
Jan 2023191035
Feb 2023118026
Mar 2023105020
Apr 2023114024
May 2023108018
Jun 2023107021
Jul 202381013
Aug 202352014
Sep 202380012
Oct 202361028
Nov 202358015
Dec 202366019
Jan 20242306
Feb 20242203
Mar 202448010
Total23330494